Co-founded by David Baker, Vilya rings in a permanent CEO; Allogene names Eric Schmidt’s CFO successornews2023-10-20T09:27:27+00:00October 20th, 2023|Endpoints News|
Merck partners with Daiichi Sankyo in ADC deal with $4B upfrontnews2023-10-20T09:05:15+00:00October 20th, 2023|Endpoints News|
Q&A: Joe Jimenez talks about salvaging ‘stuck’ drugs and why a substance abuse treatment could be worth billions of dollarsnews2023-10-20T08:58:02+00:00October 20th, 2023|Endpoints News|
Samsung’s biologics plant in South Korea receives Form 483 over data integrity, other observationsnews2023-10-19T19:08:24+00:00October 19th, 2023|Endpoints News|
Bristol Myers uncorks positive PhIII readout for subcutaneous Opdivonews2023-10-19T18:57:18+00:00October 19th, 2023|Endpoints News|
Risk-benefit determinations: FDA finalizes long-awaited guidance for drugmakersnews2023-10-19T18:52:31+00:00October 19th, 2023|Endpoints News|
Teva, Cephalon must pay $60M+ fine for reverse payment scheme after appeal failsnews2023-10-19T18:20:45+00:00October 19th, 2023|Endpoints News|
PTC to sell royalties on blockbuster SMA drug Evrysdi for up to $1.5Bnews2023-10-19T18:15:19+00:00October 19th, 2023|Endpoints News|
Merck slams ‘draconian penalties’ enforced under IRA in new court filingnews2023-10-19T17:18:30+00:00October 19th, 2023|Endpoints News|
Biocon slammed with OAI; Hong Kong looks to WuXi for ADC abilities; Tanvex Pharma launches CDMO services news2023-10-19T16:42:11+00:00October 19th, 2023|Endpoints News|
